Finkler Regulatory Affairs and Generic Drug Development Services

Finkler is an independent consultant company that has been offering first-class regulatory affairs and generic drug development services since 1996.

Led by a team of experienced professionals, Finkler offers customised regulatory affairs and development solutions to ensure fast and successful development, authorisation or maintenance of your products.

Our key services in regulatory affairs are strategic advice, documentation, regulatory project / submission management and lifecycle management / maintenance.

Strategic advice for regulatory affairs

We offer sound strategic advice for regulatory affairs. As part of our service we can work with you to develop suitable development strategies. These include:

  • Regulatory strategies for Europe
  • Pre-submission evaluation of technical data
  • Planning and handling of agency meetings (including preparation of briefing documents)
  • Due diligence for licensing projects
  • Regulatory intelligence

Regulatory affairs documentation services

Our regulatory affairs documentation services include compilation of dossiers according to Common Technical Document standards (ectd and Nees according to current requirements). Other documentation services include:

  • Chemical-pharmaceutical dossiers (CMC, Module 3): technical writing of the complete part based on customers’ raw data
  • Drug Master File: technical writing of EU Drug Master File
  • Pharmacological-toxicological and clinical documentation: compilation of dossiers based on customers’ study results
  • Preparation of SmPCs, patient leaflets and labelling
  • Quality overall summaries
  • Non-clinical summaries / overviews
  • Clinical summaries / overviews
  • Literature search in all relevant databases

Regulatory affairs project management and submission services

We ensure that your applications and dossiers meet the relevant requirements and that the documentation is prepared in a timely manner. We follow up with our customers’ internal departments and their external partners during all phases of the procedure.

We handle your decentralised and mutual recognition procedures as well as your national applications from submission to approval. Our team of experts can prepare answers to deficiency letters. We liaise with all national EU authorities and with the European Medicines Agency (EMA) at all stages of the procedure.

Regulatory maintenance and lifecycle management

For both variations and renewals state-of-the-art documents are needed to keep your products alive. We ensure that your updates are prepared according to recent EU requirements.

Generic drug development services

Our skilled team of pharmacists and medical doctors has many years of experience in the development of generic drug products within the EU. We understand that no two development projects are the same and that each customer has its own goals. This is why we tailor our services not only to meet or exceed EU regulatory agencies’ needs but also to meet specific customer requirements.

Our deep knowledge of regulatory affairs ensures that the achievements and results from development work are presented in an agency-friendly way, to ensure fast and successful approval.

Regulatory affairs training

We provide customised half-day to three-day seminars at our offices in Lörrach, Germany, or at the customer’s site.

Since regulatory affairs is our daily business the content of the programmes is based on real-world experience combined with theoretical background knowledge. Seminar options include:

  • Introductory course for secretaries and administrative staff
  • Introductory course for new DRA professionals
  • Management briefing: regulatory affairs

Make an enquiry

Finkler GmbH

Teichstrasse 66

D-79539 Lörrach



+49 76 21 16 64 44 +49 76 21 16 64 45

Finkler Images

Products and Services


White Papers

Related Projects

Ozempic (semaglutide) for the Treatment of Type 2 Diabetes

Ozempic® (semaglutide) is a glucagon-like peptide (GLP-1) receptor agonist indicated for the treatment of Type 2 diabetes in adults.

26th April 2018

Fasenra (benralizumab) for the Treatment of Asthma

Fasenra (benralizumab) is a monoclonal antibody (mAb) indicated for the treatment of severe eosinophilic asthma in patients aged 12 years and older.

27th March 2018

Zinbryta (daclizumab) for the Treatment of Multiple Sclerosis

Zinbryta (daclizumab) is an injectable formulation jointly developed by Biogen and Abbive for the treatment of relapsing forms of multiple sclerosis (MS) in adults.

22nd March 2018

Faslodex (fulvestrant) for the Treatment of Advanced Breast Cancer

Faslodex (fulvestrant) is an oestrogen receptor antagonist indicated for the treatment of locally advanced or metastatic breast cancer.

25th January 2018

Nuplazid (pimavanserin) for the treatment of Parkinson’s Disease Psychosis (PDP)

Nuplazid (pimavanserin) is an investigational drug for the treatment of Parkinson’s Disease Psychosis (PDP).

9th January 2018

Mydayis for the Treatment of Attention Deficit Hyperactivity Disorder

Mydayis is a CNS stimulant drug indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 13 years and above.

29th June 2017

Xadago (safinamide) for the Treatment of Parkinson’s Disease (PD)

Xadago® (safinamide) is a monoamine oxidase type B (MAO-B) inhibitor indicated for the treatment of Parkinson's disease.

4th April 2017

Soliqua 100/33 for the Treatment of Type 2 Diabetes

Developed by Sanofi, Soliqua 100/33 (insulin glargine & Lixisenatide injection) is indicated for the treatment of Type 2 diabetes.

18th December 2016

Adlyxin (lixisenatide) for the Treatment of Type 2 Diabetes

Adlyxin (lixisenatide) is an injectable solution developed by Sanofi for the treatment of type 2 diabetes in adults.

1st September 2016

Press Release

Regional Offices

Finkler GmbH

Teichstrasse 66

D-79539 Lörrach



+49 76 21 16 64 44 +49 76 21 16 64 45

Go Top